title: Venous thromboembolism in hematopoietic stem cell transplant recipients.
abstract: Venous thromboembolism (VTE) is an increasingly recognized problem in the post-hematopoietic stem cell transplantation (HSCT) setting, with a lack of high-quality evidence-based data to recommend best practices. Few patients with hematologic malignancies and even fewer post-HSCT patients were included in randomized trials of VTE prophylaxis and treatment. Prior VTE, GVHD, infections and indwelling venous catheters are risk factors for thrombosis. The increasing use of post-transplant maintenance therapy with lenalidomide in patients with multiple myeloma adds to this risk after autologous HSCT. These patients are also at high risk of bleeding complications because of prolonged thrombocytopenia and managing the competing risks of bleeding and thrombosis can be challenging. This review aims to provide a practical, clinician-focused approach to the prevention and treatment of VTE in the post-HSCT setting.
authors.affiliation: Hematology and Stem Cell Transplantation Section, Division of Hematology/Oncology, Department of Medicine, Vanderbilt University Medical Center and Veterans Affairs Medical Center, Nashville, TN, USA.
authors.forename: S
authors.initials: S
authors.lastname: Chaturvedi
authors.affiliation: Benign Hematology Program, Department of Hematologic Oncology and Blood Disorders, Cleveland Clinic, Cleveland, OH, USA.
authors.forename: A
authors.initials: A
authors.lastname: Neff
authors.affiliation: Hematology Division, Department of Medicine, Chaim Sheba Medical Center, Tel Hahomer, Israel.
authors.forename: A
authors.initials: A
authors.lastname: Nagler
authors.affiliation: University of Michigan, Ann Arbor, MI, USA.
authors.forename: U
authors.initials: U
authors.lastname: Savani
authors.affiliation: Department of Haematology, Saint Antoine Hospital, Paris, France.
authors.forename: M
authors.initials: M
authors.lastname: Mohty
authors.affiliation: Hematology and Stem Cell Transplantation Section, Division of Hematology/Oncology, Department of Medicine, Vanderbilt University Medical Center and Veterans Affairs Medical Center, Nashville, TN, USA.
authors.forename: B N
authors.initials: BN
authors.lastname: Savani
mesh_terms: D064591:Allografts; D006086:Graft vs Host Disease / Q000209:etiology / Q000517:prevention & control; D018380:Hematopoietic Stem Cell Transplantation / Q000009:adverse effects*; D006801:Humans; D000077269:Lenalidomide; D009101:Multiple Myeloma / Q000628:therapy*; D011183:Postoperative Complications / Q000517:prevention & control*; D013792:Thalidomide / Q000031:analogs & derivatives* / Q000627:therapeutic use; D054556:Venous Thromboembolism / Q000209:etiology / Q000517:prevention & control*
chemical_list: D013792:Thalidomide; D000077269:Lenalidomide